You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
Life Genomics markets a noninvasive prenatal test for chromosomal abnormalities, a genetic disease carrier test, and an Alzheimer's disease risk test.
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
Aetna's move comes at a time when a number of insurers including UnitedHealthcare have begun offering coverage of NIPT for average-risk pregnancies.
Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.
The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.